Journal Article

DKFZ-2018-01952

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.

Korshunov, A. (First author)DKFZ* ; Chavez, L.DKFZ* ; Sharma, T. ; Ryzhova, M. ; Schrimpf, D. ; Stichel, D. ; Capper, D.DKFZ* ; Sturm, D.DKFZ* ; Kool, M.DKFZ* ; Habel, A. ; Kleinschmidt-DeMasters, B. K. ; Rosenblum, M. ; Absalyamova, O. ; Golanov, A. ; Lichter, P.DKFZ* ; Pfister, S.DKFZ* ; Jones, D.DKFZ* ; Perry, A. ; von Deimling, A. (Last author)DKFZ*

2018
Wiley-Blackwell Oxford

This record in other databases:  

Please use a persistent id in citations: doi:10.1111/bpa.12566

Abstract: Epithelioid glioblastoma (eGBM) is a newly defined and rare GBM variant in the current WHO 2016 classification. BRAF V600E mutation is overrepresented in these tumors and there is known some morphological overlap with anaplastic epithelioid PXA (ePXA). In order to further elucidate this diagnostic category, we molecularly characterized 64 pediatric and adult examples initially diagnosed as 'eGBM.' Tumors were analyzed using array based methylation and direct sequencing of the BRAF and TERT genes. Our results demonstrated considerable molecular and clinical heterogeneity among eGBM cohort. Methylation patterns, copy number alterations, and mutational analysis data, in combination with clinical findings disclosed three different, well established tumor subtypes: (i) PXA-like tumors with favorable prognosis, predominantly in children and young adults (38), (ii) IDHwt GBM-like tumors with poor prognosis, mainly occurring in older adults, albeit with more frequent BRAF mutations (17), and (iii) RTK1 pediatric GBM-like neoplasms of intermediate prognosis in children and young adults, associated with chromothripsis and frequent PDGFRA amplifications (9). We conclude that the histopathologically defined eGBM do not represent a single diagnostic entity, but rather at least three molecularly and biologically distinct categories. Therefore, additional molecular testing through genome-wide molecular profiling is recommended to further stratify these rare cases.

---

Contributing Institute(s):

1. KKE Neuropathologie (G380)
2. B062 Pädiatrische Neuroonkologie (B062)
3. DKTK Heidelberg (L101)
4. B060 Molekulare Genetik (B060)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2018

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---